Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NIH Director Nominee Collins May Push Translational Medicine Into Spotlight

Executive Summary

Francis Collins' intellectual agility and experience working on huge initiatives with a lot of moving parts - the human genome project comes to mind - will serve him well as the National Institutes of Health's director

You may also be interested in...



NIH Rare Diseases Project Could Have Broad Effect On Personalized Medicine

In a high profile effort to speed along personalized medicine, the heads of the National Institutes of Health and FDA are pointing out the possible commercial applications of seemingly small steps, such as the potential for an NIH initiative to accelerate development of therapies for rare diseases to advance personalized medicine in more common illnesses

NIH Rare Diseases Project Could Have Broad Effect On Personalized Medicine

In a high profile effort to speed along personalized medicine, the heads of the National Institutes of Health and FDA are pointing out the possible commercial applications of seemingly small steps, such as the potential for an NIH initiative to accelerate development of therapies for rare diseases to advance personalized medicine in more common illnesses

Orphans Wanted: FDA Offers New Ideas For Rare Disease Drug Development

FDA's top review managers have a message for drug developers: they are eager to find creative ways to work with sponsors to bring new treatments for rare diseases to market

Related Content

Topics

UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel